- Residency - Vanderbilt University Medical Center (2002-2006), Radiation Oncology
- Internship - Vanderbilt University Medical Center (2001-2002), Internal Medicine
- Medical School - Boston University School of Medicine (1997-2001)
- Graduate School - Boston University School of Medicine (1993-1997)
Nathan Kim, M.D., Ph.D.
- Radiation Oncology
- Breast Cancers
- Genitourinary Cancer
Nathan Kim, M.D., Ph.D., is an Associate Professor of Radiation Oncology at UT Southwestern, specializing in treatment of breast cancer. He studied engineering in college, received a master’s degree in biomedical engineering from Johns Hopkins, and earned a combined M.D./Ph.D. from Boston University in 2001.
Dr. Kim then completed an internship in internal medicine and a residency in radiation oncology at Vanderbilt University Medical Center. Board certified by the American Board of Radiology, he brought years of private practice and academic medicine experience with him when he joined the UT Southwestern faculty in 2016.
“I feel that UT Southwestern and Simmons Cancer Center continue to move at an extraordinarily fast pace in the right direction. In addition to being the only National Cancer Institute-designated comprehensive cancer center in North Texas, , we are focusing not just on basic science but also on translating the basic science into clinical practice,” Dr. Kim says. “I really feel this is a great place to be part of something special.”
Dr. Kim uses the latest radiation therapy techniques to treat breast cancer.
His research has been published in the International Journal of Radiation Oncology, Biology, Physics and other peer-reviewed publications, and he is a member of the American Society of Therapeutic Radiology and Oncology.
Meet Dr. Kim
Breast Radiation Oncologist in Dallas
Nathan Kim, M.D., Ph.D., did not start his educational career with a goal of being a radiation oncologist. In fact, his Ph.D. is in biochemistry. But his personal experience with family members and cancer while he was in medical school led him to develop a strong interest in the disease and, now, as an Associate Professor of Radiation Oncology at UT Southwestern, it has helped shape his patient care philosophy.
“I don’t just believe in short-term care but really developing a relationship with patients for long-term care so it doesn’t end when their treatment ends. I really try to follow up with them and be part of their survivorship process as well.”
“Having family members who have gone through cancer treatment and benefited from it reminds me to treat my patients the way I would want my family members treated,” Dr. Kim says. “That includes showing respect and compassion but also looking for every realistically possible option that’s out there for them.”
Especially for breast cancer, he says, there is a lot to consider.
“Depending on the patient’s specific diagnosis, there may be several viable options for treatment, and the field is constantly moving,” Dr. Kim says. “For example, should the patient consider a shorter course of radiation versus the historic standard? Should the patient consider a clinical trial or even the option of observation without therapy? Not everybody fits into a box. So, depending on the situation, patients may need more comprehensive discussion of their options.
“Part of my role is breaking things down for them and simplifying things to help them in their decision making as they go through this difficult time.”
- American Society of Therapeutic Radiology and Oncology
- Sidney Cooperband Award 2001, Boston University School of Medicine
- ASTRO Basic Science Travel Grant 2004
- ABR Holman Pathway Research Award 2004, RSNA
- RSNA Resident Trainee Award and Travel Grant 2005
- AACR AFLAC Scholars in Training Award 2005
Principles and Practice of Radiation Oncology, 6th Edition
Kim DW, Story D, Choy H(Ed.) (2013), Philadelphia, Lippincott Williams & Wilkins
CANCER: Principles and Practice of Oncology Review
Choy H, Kim DWN(Ed.) (2012), Philadelphia, Lippincott Williams & Wilkins
- Principles and Practice of Radiation Oncology, 6th Edition
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE The Journal of clinical investigation 1997 Dec 100 12
Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells.
Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, Hafer LJ, Yaswen P, Stampfer M, Rogers AE, Russo J, Sonenshein GE Carcinogenesis 2000 May 21 5
The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells.
Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GE Oncogene 2000 Nov 19 48
Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis.
Trombino AF, Near RI, Matulka RA, Yang S, Hafer LJ, Toselli PA, Kim DW, Rogers AE, Sonenshein GE, Sherr DH Breast cancer research and treatment 2000 Sep 63 2
Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture.
Kavanagh KT, Hafer LJ, Kim DW, Mann KK, Sherr DH, Rogers AE, Sonenshein GE Journal of cellular biochemistry 2001 82 3 387-98
Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.
Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, Sonenshein GE Oncogene 2001 Mar 20 14
Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.
Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE Molecular and cellular biology 2003 Aug 23 16
Chemotherapy and irradiation interaction.
Choy H, Kim DW Seminars in oncology 2003 Aug 30 4 Suppl 9
Combined modality therapy for non-small cell lung cancer, past, present, and future.
Kim DW, Choy H Lung cancer (Amsterdam, Netherlands) 2003 Dec 42 Suppl 2
Rationale for investigation of epidermal growth factor receptor inhibitors in definitive treatment of locally advanced non-small cell lung cancer and head and neck cancer.
Choy H, Kim DW Seminars in respiratory and critical care medicine 2004 25 Suppl 1
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Kim DW, Choy H International journal of radiation oncology, biology, physics 2004 59 2 Suppl
Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
Kim DW, Lu B, Hallahan DE Current opinion in investigational drugs (London, England : 2000) 2004 Jun 5 6
Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer.
Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H. Lung Cancer 2005 2 50 235-45
Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.
DW Kim, Y Shyr, H Chen, W Akerley, DH Johnson, H Choy International Journal of Radiation Oncology Biology Physics 2005 Nov 15 4 63 1029-36
Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging.
Yankeelov TE, Niermann KJ, Huamani J, Kim DW, Quarles CC, Fleischer AC, Hallahan DE, Price RR, Gore JC Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2006 Apr 25 4
Noninvasive assessment of tumor vasculature response to radiation-mediated, vasculature-targeted therapy using quantified power Doppler sonography: implications for improvement of therapy schedules.
Kim DW, Huamani J, Niermann KJ, Lee H, Geng L, Leavitt LL, Baheza RA, Jones CC, Tumkur S, Yankeelov TE, Fleischer AC, Hallahan DE Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2006 Dec 25 12
STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
Geng L, Shinohara ET, Kim D, Tan J, Osusky K, Shyr Y, Hallahan DE International journal of radiation oncology, biology, physics 2006 Jan 64 1
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Kim DW, Huamani J, Fu A, Hallahan DE International journal of radiation oncology, biology, physics 2006 Jan 64 1
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B International journal of radiation oncology, biology, physics 2007 Feb 67 2
Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.
Niermann KJ, Fleischer AC, Huamani J, Yankeelov TE, Kim DW, Wilson WD, Hallahan DE Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2007 Jun 26 6
Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models.
Huamani J, Willey C, Thotala D, Niermann KJ, Reyzer M, Leavitt L, Jones C, Fleishcher A, Caprioli R, Hallahan DE, Kim DW International journal of radiation oncology, biology, physics 2008 May 71 1
DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor.
Yu L, Tumati V, Tseng SF, Hsu FM, Kim DN, Hong D, Hsieh JT, Jacobs C, Kapur P, Saha D Neoplasia (New York, N.Y.) 2012 Dec 14 12 1203-12
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.
Kim DN, Nam TK, Choe KS, Choy H Cancer research and treatment : official journal of Korean Cancer Association 2012 Jun 44 2 74-84
Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.
Straka C, Kim DW, Timmerman RD, Pedrosa I, Jacobs C, Brugarolas J Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Aug 31 23 e401-3
Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
Jacobs C, Kim DW, Straka C, Timmerman RD, Brugarolas J Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Mar 31 7 e114-7
Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study.
Kim DW, Straka C, Cho LC, Timmerman RD Frontiers in oncology 2014 4 319
Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long-term Survivor with Metastatic Non-Small-Cell Lung Cancer.
Arreola KN, Ying J, Hughes R, Gerber DE, Kim DW Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2014 Aug 9 8 e60-1
Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L, Kim DN, Hannan R, Watumull LM, Brugarolas J Clinical genitourinary cancer 2014 Dec
Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.
Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD International journal of radiation oncology, biology, physics 2014 Jul 89 3 509-17
Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy.
Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R, Lotan Y, Roehrborn CG, Choe KS, Kim DN Cancer biology & therapy 2014 Mar 15 6
DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy.
Jacobs C, Tumati V, Kapur P, Yan J, Hong D, Bhuiyan M, Xie XJ, Pistenmaa D, Yu L, Hsieh JT, Saha D, Kim DW International journal of radiation oncology, biology, physics 2014 May
Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab.
Law JY, Kim DW, Sturgis A, Naina HV Clinical Medicine Insights. Oncology 2015 9 61-3
Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy.
Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D Cancer medicine 2015 Dec 4 12 1844-52
Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
Ying J, Wang CJ, Yan J, Liauw SL, Straka C, Pistenmaa D, Xie XJ, Lotan Y, Roehrborn C, Kim DN American journal of clinical oncology 2015 Jul
Stereotactic Radiation Therapy of Renal Cancer Inferior Vena Cava Tumor Thrombus.
Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, Sagalowsky A, Pedrosa I, Choy H, Brugarolas JB, Timmerman RD Cancer biology & therapy 2015 Mar 0
Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome.
Straka C, Ying J, Kong FM, Willey CD, Kaminski J, Kim DW SpringerPlus 2016 5 229
Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients.
Shiao J, Thomas KM, Rahimi AS, Rao R, Yan J, Xie XJ, DaSilva M, Spangler A, Leitch M, Wooldridge R, Rivers A, Farr D, Haley B, Kim DW Breast cancer research and treatment 2016 Dec
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.
Wang CJ, Ying J, Kapur P, Wohlfeld B, Roehrborn C, Kim DW Oncology letters 2016 Jan 11 1 713-716
Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial.
Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R Practical radiation oncology 2016 Jun
Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.
Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, Lotan Y, Timmerman R European journal of cancer (Oxford, England : 1990) 2016 May 59 142-51
Constructing a Clinicopathologic Prognostic Model for a Triple Negative Breast Cancer Population
Kimberly Thomas, MD, MSc; Jean Shiao, BS; Roshni Rao, MD; Abu Minhajuddin, PhD; Ann Spangler, MD, MACM; Marilyn Leitch, MD; Rachel Wooldridge, MD; Aeisha Rivers MD; Barbara Haley; MD, DW; Nathan Kim, MD, PhD; and Asal Rahimi, MD, MS American Journal of Hematology/Oncology 2017 13 1 11-21
Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials.
Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, Kim DWN, Hornberger B, Dubas J, Laine AM, Zelefsky MJ, Timmerman RD, Folkert MR Medical dosimetry : official journal of the American Association of Medical Dosimetrists 2017 Jul
Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair.
Mohamad O, Sishc BJ, Saha J, Pompos A, Rahimi A, Story MD, Davis AJ, Kim DWN Cancers 2017 Jun 9 6
Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky A, Gahan J, Laine A, Xie XJ, Choy H, Brugarolas J, Timmerman R, Hannan R International journal of radiation oncology, biology, physics 2017 May 98 1 91-100
Emphasis on Repair, Not Just Avoidance of Injury, Facilitates Prudent Stereotactic Ablative Radiotherapy.
Kim DWN, Medin PM, Timmerman RD Seminars in radiation oncology 2017 Oct 27 4 378-392
- Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
- Use of aspirin in locally advanced cancer
- Particle therapy applications for breast cancer
- Optimizing advanced technology utilization for radiation therapy
- Mitigation of normal tissue injury from radiation therapy
- Combined modality therapy for breast cancer
- Breast Cancers
- Genitourinary Cancer
- Brain Metastases
- Cancer Genetics
- Kidney Cancer
Q&A by Dr. Kim
Showing 2 locations